| Literature DB >> 19114073 |
Jun-Song Lin1, Yi-Han Chiu, Nien-Tsung Lin, Chia-Hsiang Chu, Kuo-Chin Huang, Kuang-Wen Liao, Kou-Cheng Peng.
Abstract
Treatment and prevention of pediatric infectious diseases of three commercial probiotic products were evaluated by a double-blind, randomized, controlled trial. Test subjects under age 5, 1062 in total, were distributed randomly into four groups. This investigation showed that L. casei rhamnosus can control bacterial, viral and respiratory infections; a multi-species probiotic reduced gastrointestinal disease significantly. Long-term consumption of L. rhamnosus T cell-1 decreased the incidence of bacterial infection.Entities:
Mesh：
Year: 2008 PMID： 19114073 DOI： 10.1016/j.vaccine.2008.11.114
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641